Acumen Pharmaceuticals, Inc. (ABOS)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.22
- As of
Kresmion compiles this page from ABOS's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Acumen Pharmaceuticals, Inc. (ABOS): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-05.
See the full ABOS dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ABOS on one page. Preview it with sample data, then open it live with a free account.
Preview the ABOS dossierActive events for ABOS
- mediumEarnings above estimates
Q3-2026: Beat consensus by 11.8%, EPS $-0.35 vs $-0.3968 estimate
- high13F: large reduction
CITADEL ADVISORS LLC cut 85% of ABOS (2026Q2)
- high13F: large reduction
MILLENNIUM MANAGEMENT LLC cut 91% of ABOS (2026Q2)
- mediumEarnings below estimates
Q2-2026: Missed consensus by 20.2%, EPS $-0.45 vs $-0.3745 estimate
- high13F: large increase
Point72 Asset Management, L.P. added +85% to ABOS (2026Q1)
FREE, NO ACCOUNT
Every event on ABOS, as it fires
You are seeing 5 of 10 events recorded on ABOS since 2026-05-16.
The five above landed across 4 days. The other 5 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
ABOS positions held by the managers we follow (2026Q2)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC FundCUSIP 00509G209 · 2026Q2 | $1.8M | 0.00% |
| TWO SIGMA INVESTMENTS, LP FundCUSIP 00509G209 · 2026Q2 | $1.7M | 0.00% |
| MILLENNIUM MANAGEMENT LLC FundCUSIP 00509G209 · 2026Q2 | $162K | 0.00% |
| CITADEL ADVISORS LLC FundCUSIP 00509G209 · 2026Q2 | $136K | 0.00% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ABOS
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
Going concern statement
ABOS's 10-Q filed Oct 26, 2026 states:
Accordingly, the Company has concluded that substantial doubt exists about its ability to continue as a going concern.
Read the 10-Q on SEC EDGAR Every company with a going concern statement
More data on ABOS
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in ABOS on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on ABOS in the last 180 days.
Upstream: SEC EDGAR filings for ABOS
Kresmion, "Acumen Pharmaceuticals, Inc. (ABOS) institutional holdings and SEC filings", data as of 2026-11-05, https://kresmion.com/research/ABOS. Upstream data: SEC EDGAR filings for ABOS.
Link to this data (HTML):
<a href="https://kresmion.com/research/ABOS">Acumen Pharmaceuticals, Inc. (ABOS) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow ABOS on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to ABOS for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.